Methylation Analysis: Predicting Glioblastoma Treatment Response

A lab performs O–6–methylguanine–DNA methyltransferase (MGMT) promoter methylation analysis, typically as a prognostic marker for responsiveness of glioblastoma (brain tumor) to alkylating chemotherapy using temozolomide. Choose a location to see hospital-reported price summaries. This page does not show national, sample, or aggregate pricing.